Guidelines for ATC classification and DDD assignment - WHOCC

Hormonal contraceptives, see G03A.
Estrogens used only in neoplastic diseases, see L - Antineoplastic and
immunomodulating agents.
The DDDs are based on systemic use in postmenopausal estrogen
substitution therapy and in the treatment of premenstrual ailments.
However, for some preparations for vaginal administration the
DDDs are based on local treatment.
The DDDs for transdermal preparations are based on the amount of
active ingredient delivered per 24 hours and the number of days
each patch is used.
G03CA Natural and semisynthetic estrogens, plain
This group comprises preparations, which contain one or more natural
or semisynthetic estrogen. Estradiol/polyestradiol are classified at the
same 5th level. The same applies to estriol/polyestriol. Combinations
of estradiol and estriol are classified in G03CA53.
Combinations with other drugs, see G03CC.
Estropipate is classified in G03CA07 - estrone.
The DDD for nasal administration of estradiol is based on daily
treatment. No DDD for estradiol vaginal ring has been established.
G03CB Synthetic estrogens, plain
This group comprises preparations, which contain synthetic estrogens
only.
Combinations with other drugs, see G03CC.
G03CC Estrogens, combinations with other drugs
This group includes combined preparations with natural, semisynthetic
or synthetic estrogens and other drugs.
149